Fig. 3From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trialsProportion of participantsa,b with ≥ 50% (a, b) or ≥ 75% (c, d) reduction in MAMD. CM, chronic migraine; EM, episodic migraine; MAMD, monthly average migraine days; SE, standard error. aFor participants with EM, response was defined as a reduction of ≥ 2 MAMD. bFor participants with CM, response was defined as a reduction of ≥ 4 MAMDBack to article page